Edition:
United States

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

7.15USD
20 Sep 2018
Change (% chg)

-- (--)
Prev Close
$7.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
83,618
52-wk High
$15.20
52-wk Low
$6.15

Latest Key Developments (Source: Significant Developments)

Syndax Pharmaceuticals Reports Q1 Loss Per Share $0.79
Tuesday, 8 May 2018 04:05pm EDT 

May 8 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE.Q1 LOSS PER SHARE $0.79.Q1 EARNINGS PER SHARE VIEW $-0.96 -- THOMSON REUTERS I/B/E/S.SYNDAX PHARMACEUTICALS - PFS RESULTS FROM PIVOTAL PHASE 3 E2112 TRIAL OF ENTINOSTAT PLUS EXEMESTANE IN HR+, HER2- BREAST CANCER EXPECTED IN 3Q18.SYNDAX PHARMACEUTICALS - FOR Q2 AND FY 2018, RESEARCH AND DEVELOPMENT EXPENSES EXPECTED TO BE $15 TO $18 MILLION AND $62 TO $70 MILLION, RESPECTIVELY.  Full Article

Syndax Pharmaceuticals Reports Qtrly Loss Per Share $0.80
Monday, 5 Mar 2018 04:23pm EST 

March 5 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS - PHASE 2 ENCORE 601 PD-(L)1 REFRACTORY MELANOMA COHORT DATA AND MELANOMA REGISTRATION STRATEGY DISCLOSURE FORTHCOMING IN 2Q18.SYNDAX PHARMACEUTICALS INC - ENCORE 601 PD-(L)1 REFRACTORY NSCLC COHORT DATA EXPECTED 2Q18.SYNDAX PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.80.SYNDAX PHARMACEUTICALS INC - FOR Q1 RESEARCH AND DEVELOPMENT EXPENSES ARE EXPECTED TO BE $18 TO $22 MILLION.SYNDAX PHARMACEUTICALS INC - FOR FULL YEAR 2018 RESEARCH AND DEVELOPMENT EXPENSES ARE EXPECTED TO BE $67 TO $76 MILLION.SYNDAX PHARMACEUTICALS INC - TOTAL OPERATING EXPENSES ARE EXPECTED TO BE $22 TO $26 MILLION FOR Q1.SYNDAX PHARMACEUTICALS INC - TOTAL OPERATING EXPENSES ARE EXPECTED TO B $86 TO $96 MILLION FOR FULL YEAR 2018.  Full Article

Syndax Pharmaceuticals Reports Q4 Loss Per Share $0.80
Monday, 5 Mar 2018 04:05pm EST 

March 5 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE.Q4 LOSS PER SHARE $0.80.SYNDAX PHARMACEUTICALS - FOR Q1 AND FY 2018, TOTAL OPERATING EXPENSES ARE EXPECTED TO BE $22 TO $26 MILLION AND $86 TO $96 MILLION, RESPECTIVELY.Q4 EARNINGS PER SHARE VIEW $-0.78 -- THOMSON REUTERS I/B/E/S.  Full Article

Syndax Announces Immuno-Oncology Clinical Trial Collaboration With Astrazeneca
Thursday, 1 Feb 2018 07:00am EST 

Feb 1 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX ANNOUNCES IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION WITH ASTRAZENECA.SYNDAX PHARMACEUTICALS INC - CO & ASTRAZENECA TO COLLABORATE ON NON-EXCLUSIVE BASIS TO EVALUATE COMBINATION OF TWO DRUGS IN MULTIPLE SOLID TUMOR TYPES.SYNDAX PHARMACEUTICALS INC - SYNDAX EXPECTS TO INITIATE A PHASE IB STUDY IN FIRST HALF OF 2018.SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer
Wednesday, 10 Jan 2018 07:00am EST 

Jan 10 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER.SYNDAX PHARMACEUTICALS INC - NEW CLINICAL COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP.SYNDAX PHARMACEUTICALS - COS WILL EVALUATE COMBINATION OF CO'S ENTINOSTAT AND GENENTECH'S ATEZOLIZUMAB.SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED..SYNDAX PHARMACEUTICALS INC - GENENTECH WILL BE RESPONSIBLE FOR CONDUCTING TRIAL.SYNDAX PHARMACEUTICALS INC - TRIAL WILL BE CONDUCTED AS PART OF MORPHEUS, ROCHE'S NOVEL CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM.  Full Article

Syndax Pharmaceuticals reports Q3 loss per share $0.68
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update.Q3 loss per share $0.68.Q3 earnings per share view $-0.80 -- Thomson Reuters I/B/E/S.  Full Article

Syndax Pharma enters into license agreement with unit of Allergan
Tuesday, 17 Oct 2017 07:53am EDT 

Oct 17 (Reuters) - Syndax Pharmaceuticals :On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing.Pursuant to agreement, co will make an upfront payment of $5.0 million to Allergan​.If parties commercialize Menin assets, co obligated to pay Allergan low single to low double-digit royalties on sales​.Under agreement, Allergan grants co worldwide license to portfolio of orally-available small molecule inhibitors of interaction of MLL protein​.Under agreement, may have to pay allergan up to $99 million in one-time development, regulatory milestone payments subject to achievement of milestones.In event of commercializing Menin assets, co to also pay up to $70 million in potential one-time sales-based milestone payments​.Company will be solely responsible for development and commercialization of Menin assets​.Under certain circumstances, co may be required to share a percentage of non-royalty income from sublicensees, with Allergan​.  Full Article

Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​
Tuesday, 17 Oct 2017 07:00am EDT 

Oct 17 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​.Syndax Pharmaceuticals Inc - ‍ entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, inc., a subsidiary of Allergan PLC​.  Full Article

Syndax Pharmaceuticals Q2 loss per share $0.70
Thursday, 10 Aug 2017 04:05pm EDT 

Aug 10 (Reuters) - Syndax Pharmaceuticals Inc :Syndax Pharmaceuticals reports second quarter 2017 financial results and provides clinical and business update.Q2 loss per share $0.70.Q2 earnings per share view $-0.83 -- Thomson Reuters I/B/E/S.Syndax Pharmaceuticals Inc - ‍for Q3 research and development expenses are expected to be $12.0 to $14.0 million​.Syndax Pharmaceuticals Inc - ‍for full year 2017, research and development expenses are expected to be $46.0 to $51.0 million​.  Full Article

Syndax prices public offering of common stock
Wednesday, 24 May 2017 08:05pm EDT 

May 24 (Reuters) - Syndax Pharmaceuticals Inc :Syndax prices public offering of common stock.Pricing of an underwritten public offering of 3.7 million shares of its common stock at a price to public of $13.25 per share.  Full Article

BRIEF-Syndax Announces Updated Results From Phase 2 Encore 601 Trial Of Entinostat In Combination With Keytruda®

* SYNDAX ANNOUNCES UPDATED RESULTS FROM PHASE 2 ENCORE 601 TRIAL OF ENTINOSTAT IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB)